Canaccord Genuity Maintains Buy on Waldencast, Raises Price Target to $3
Waldencast Sells Obagi Medical To Bridgepoint For Up To $460M
Obagi Medical Announces New Skincare And Filler Data At Nashville SCALE Meeting
Reported Earlier, Waldencast Announces SEC Concludes Investigation With No Enforcement Action Recommended Against The Company
Waldencast's Obagi Medical Announces Collaboration With ProMD Health As Part Of Obagi's Hyaluronic Acid Program
Telsey Advisory Group Maintains Market Perform on Waldencast, Lowers Price Target to $2
Canaccord Genuity Maintains Buy on Waldencast, Lowers Price Target to $2
Waldencast FY EPS $(2.01) Misses $(0.41) Estimate, Sales $272.071M Miss $286.017M Estimate
Obagi Medical Announces Schweiger Dermatology As Partner In Aesthetics Leadership With Hyaluronic Acid Program
Obagi Medical Announces Its Secret Med Spa As Partner In Aesthetics Leadership With Hyaluronic Acid Program
Waldencast, Obagi Medical Announce Aesthetic Record As Partner For Aesthetics Leadership
Waldencast: Strategic Reviews Are More Than Necessary
How The Story Behind Waldencast (WALD) Is Shifting In Analysts’ Eyes
Obagi Medical and DermFx Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
Waldencast's Obagi Medical Announces DermFx As Key Partner For Aesthetics Leadership With Obagi's Hyaluronic Acid Program
Obagi Medical and Moxie Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
Obagi Medical Partners With Moxie In The ALOHA Program To Evaluate saypha MagIQ Filler's Performance Across Aesthetic Practices
Obagi Medical Introduces New Lip Therapy Protocol Designed to Resurface, Replenish, and Protect
Waldencast's Obagi Medical Launches Two New Lip Therapy Products, AHA + PHA Smoothing Micro‑Peel And Soothe & Protect Lip Treatment SPF 30, As Targeted Treatment Protocol
Obagi Medical and VIO Med Spa Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.